American Century Companies Inc. Buys 22,311 Shares of Owens & Minor, Inc. (NYSE:OMI)

American Century Companies Inc. increased its stake in Owens & Minor, Inc. (NYSE:OMI) by 14.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 172,878 shares of the company’s stock after acquiring an additional 22,311 shares during the quarter. American Century Companies Inc. owned 0.23% of Owens & Minor worth $2,334,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of OMI. Norges Bank bought a new stake in Owens & Minor during the 4th quarter valued at $9,160,000. Franklin Resources Inc. increased its stake in Owens & Minor by 21.7% during the 4th quarter. Franklin Resources Inc. now owns 51,096 shares of the company’s stock valued at $985,000 after purchasing an additional 9,121 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Owens & Minor during the 4th quarter valued at $852,000. Gabelli Funds LLC increased its stake in Owens & Minor by 14.9% during the 4th quarter. Gabelli Funds LLC now owns 135,000 shares of the company’s stock valued at $2,601,000 after purchasing an additional 17,500 shares in the last quarter. Finally, Quarry LP increased its stake in Owens & Minor by 38.8% during the 4th quarter. Quarry LP now owns 2,573 shares of the company’s stock valued at $50,000 after purchasing an additional 719 shares in the last quarter. Institutional investors own 98.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Barclays decreased their price target on shares of Owens & Minor from $23.00 to $18.00 and set an “equal weight” rating for the company in a research note on Monday, August 5th. Robert W. Baird reduced their target price on shares of Owens & Minor from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, July 16th. Citigroup upgraded shares of Owens & Minor from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $24.00 to $19.00 in a research note on Friday, July 19th. Bank of America reduced their target price on shares of Owens & Minor from $18.00 to $16.00 and set an “underperform” rating for the company in a research note on Tuesday, June 25th. Finally, StockNews.com lowered shares of Owens & Minor from a “buy” rating to a “hold” rating in a research note on Monday, August 26th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Owens & Minor has an average rating of “Hold” and a consensus target price of $20.00.

Owens & Minor Price Performance

Shares of NYSE:OMI opened at $16.18 on Friday. The company’s 50-day moving average is $15.58 and its 200 day moving average is $18.51. The company has a debt-to-equity ratio of 2.17, a quick ratio of 0.51 and a current ratio of 1.09. The company has a market capitalization of $1.24 billion, a P/E ratio of -31.73, a price-to-earnings-growth ratio of 0.49 and a beta of 0.39. Owens & Minor, Inc. has a fifty-two week low of $12.36 and a fifty-two week high of $28.35.

Owens & Minor (NYSE:OMI) last released its quarterly earnings data on Friday, August 2nd. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.33 by $0.03. The business had revenue of $2.67 billion for the quarter, compared to the consensus estimate of $2.65 billion. Owens & Minor had a negative net margin of 0.40% and a positive return on equity of 14.66%. The company’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.18 earnings per share. On average, equities research analysts forecast that Owens & Minor, Inc. will post 1.57 earnings per share for the current year.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.